<DOC>
	<DOCNO>NCT02690142</DOCNO>
	<brief_summary>The purpose first-in-human study investigate safety tolerability ABY-035 administer intravenously subcutaneously , healthy volunteer moderate-to-severe psoriasis patient .</brief_summary>
	<brief_title>A Study Investigate Safety , Tolerability Pharmacokinetics ABY-035</brief_title>
	<detailed_description>This first human study ABY-035 ( novel IL-17A inhibitor ( interleukin 17A ) ) consist four Parts . Part A consists single ascend intravenous dose study 40 healthy volunteer divide five dose cohort . Each group consist 8 subject 6 subject receive ABY-035 2 receive placebo . The subject follow pharmacokinetic safety assessment Day 95 dosing . Part B study consist 6 healthy volunteer give single subcutaneous dose ABY-035 . The subject follow study visit schedule Part A . Part C study include 12 moderate-to-severe psoriasis patient patient give single intravenous dose ABY-035 . The patient follow study visit schedule Part A B . Part D study include 6 moderate-to-severe psoriasis patient . Each patient participate 3 dose occasion subcutaneously administer ABY-035 Day 1 , Day 15 Day 29 . Patients follow regularly safety efficacy 16 week post-final dose .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Part A , Part B Males females 18 65 year age Body mass index ( BMI ) 18.0 kg/m2 32.0 kg/m2 , inclusive . maximum body weight 120 kg In good health , determine medical history , physical examination , vital sign assessment , 12 lead electrocardiogram ( ECG ) clinical laboratory evaluation . Subjects give write informed consent participate study In addition Part C D Males females 18 65 year age Body mass index ( BMI ) 18.0 kg/m2 39.9 kg/m2 , inclusive . Minimum body weight 45 kg Patients must diagnosis moderate severe plaque type psoriasis ( confirmed dermatologist ) least 6 month prior administration study drug without document flare within 30 day prior Screening . Patients concurrent psoriatic arthritis may enrol . Have plaque type psoriasis cover least 10 % total body surface area ( BSA ) Screening Baseline ( Day 1 ) . Have PASI score 12 great Screening Baseline ( Day 1 ) . Exclusion criterion : Part A , Part B , Part C Part D Subjects clinically significant medical history , determine investigator Subjects smoke 15 cigarette , equivalent , per day Alcohol and/or drug abuse Positive HIV , Hepatitis B , Hepatitis C , tuberculosis Subjects receive live vaccination within 3 month prior Screening Subjects pregnant lactating Subjects agree use appropriate contraception Subjects history anaphylaxis , drug allergy clinically significant allergic condition ( exclude non active hayfever ) Participation another clinical trial Subjects , opinion investigator , participate study In addition Part C D Patients currently non plaque form psoriasis ( eg , erythrodermic , guttate , pustular ) Patients current drug induce psoriasis Have history use participate clinical trial therapeutic agent directly target IL 17 cytokine receptor Have receive phototherapy within 4 week prior Day 1 Patients receive systemic medication treatment could affect psoriasis PASI evaluation ( include , limited , oral injectable corticosteroid , retinoids , 1,25 dihydroxy vitamin D3 analogue , fumaric acid ester , psoralens , anti TNF ( tumour necrosis factor ) biologics , anti IL 12/23 biologics , herbal treatment ) , within 5 half life prior Day 1 ( 4 week oral anti psoriatics , 12 week psoralens PUVA ( oral psoralen ultraviolet A ) , 24 week biologics ) Patients use topical medication treatment could affect psoriasis PASI evaluation ( eg , corticosteroid , coal tar , anthralin , calcipotriene , topical vitamin D derivative , retinoids , tazarotene , methoxsalen , trimethyl psoralens ) within 2 week administration IMP ( Investigational Medicinal Product ) Patients use systemic immunosuppressant ( eg , methotrexate , azathioprine , cyclosporine , 6 thioguanine , mercaptopurine , mycophenolate mofetil , hydroxyurea , tacrolimus ) within 8 week administration IMP ( 5 half life , whichever long ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>